Fairjourney Biologics

What Fairjourney Biologics does

FairJourney Biologics is a privately-held contract research organization (CRO) founded in 2012 in Porto, Portugal, that provides end-to-end antibody discovery, engineering, and development services to pharmaceutical companies, biotechnology firms, and academic institutions globally. The company operates four sites (Porto headquarters, Cambridge UK, San Diego, and South San Francisco) and employs more than 250 scientists, having completed over 1,130 projects for more than 245 partners and contributed to 19+ antibodies that have advanced into clinical stages.

The company's competitive core is built around proprietary display and library platforms — Mammalian Display (with granted patents covering both the platform and its developability-selection methodology), the Explorer Library, SuperHuman 2.0, Cosmic, and Tungsten VHH libraries, plus B-Cell Navigator single B-cell screening, Yeast Display, and a cryo-EM structural biology facility equipped with two ThermoFisher Titan Krios 5 systems. These platforms are integrated into a single workflow that spans immunization (via the newly licensed AbTherx Atlas transgenic mice), antibody discovery, engineering, humanization, affinity maturation, protein production, biophysical characterization (GLP-certified), cell line development (CHO GS-/- platform with >100 clinical molecules), and biologistics sample management.

Revenue is generated through project-based, fee-for-service contracts sold via a dedicated business development and account management team, with pricing quoted per program rather than via published tiers. Customer mix spans large pharma (Daiichi Sankyo, Genmab), mid-market biotech (Merus, argenx, Paragon Therapeutics, Viridian Therapeutics), and smaller virtual companies (Capella Bioscience), supporting a horizontally diversified revenue base. The company has received funding from GHO Capital (2020) and multiple EU Portugal 2020 grants, and operates GLP-certified labs that support IND-enabling work, positioning it as a regulated, mid-sized specialty CRO within the outsourced antibody discovery market.

Name

Fairjourney Biologics

Legal name

FairJourney Biologics, S.A.

Website

https://fjbio.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

251–500 employees

Short description

FairJourney Biologics is a privately-held antibody discovery and development CRO founded in 2012 that provides end-to-end services from immunization to cell line development to pharma, biotech, and academic clients worldwide using proprietary display, library, and cryo-EM platforms across sites in Porto, Cambridge, San Diego, and San Francisco.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Antibody discovery services
• Biologics contract research
• Antibody engineering
• Cell line development
• Cryo-EM structural biology

Headquarters

HQ city

Oporto

HQ country

Portugal

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services (CRO): FairJourney Biologics operates as a Contract Research Organization (CRO) providing fee-for-service antibody discovery, engineering, and development programs. Revenue is generated through project-based service contracts with pharmaceutical companies, biotech firms, and academic institutions. Programs span from single service modules to fully integrated end-to-end partnerships. Pricing varies by scope, complexity, and deliverables.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Core offering

FairJourney Biologics is a contract research organization (CRO) providing end-to-end antibody discovery, engineering, and development services to pharmaceutical companies, biotechnology firms, and academic institutions. Services span antibody discovery via proprietary Mammalian Display, phage display, yeast display, and B-Cell Navigator platforms, antibody engineering and humanization, protein production, functional and biophysical characterization (GLP-certified), cryo-EM structural biology, biologistics, and CHO GS-/- cell line development.

Product overview

FairJourney Biologics offers an integrated platform of antibody discovery, engineering, and development services organized around proprietary technologies and comprehensive service modules. The core offering centers on the B-Cell Navigator platform for single B-cell screening integrated with the proprietary Mammalian Display technology for developability-optimized antibody selection. The technology portfolio includes multiple proprietary and licensed antibody libraries (Explorer Library, SuperHuman Library with Cosmic and Tungsten variants, Atlas Mice transgenic technologies) and display platforms (Mammalian Display, Phage Display, Yeast Display). Service capabilities span the full antibody lifecycle: antibody discovery, antibody engineering, protein production, functional analysis, biophysical characterization (GLP-certified), cell line services (engineering and development), biologistics, and cryo-EM structural biology services. The cryo-EM offering includes AI-powered capabilities for epitope-based hit discovery and structure-based design. All services can be accessed individually or as an integrated end-to-end workflow managed by a single team across global sites.

Differentiator

Problem solved

Functional benefit

Brands

• Mammalian Display: Proprietary clinically validated antibody engineering platform enabling generation of high-quality antibody leads with optimal biophysical properties through FACS-based selections.
• Explorer Library
• B-Cell Navigator
• SuperHuman Library
• Cosmic Library
• Tungsten Libraries
• The Antibody Series

Products and services

• Antibody Discovery Core service leveraging phage display and proprietary Mammalian Display technologies to generate target-specific antibodies from immune and non-immune repertoires. Supports multiple species immunizations (mouse, rat, rabbit, chicken, llama) and transgenic animals.
• Antibody Engineering Services improving antibody performance, quality, and versatility including humanization, affinity maturation, and format optimization for therapeutic leads.
• Protein Production Antibody and antigen production from high-throughput early-stage discovery to multigram scale for late-stage characterization. Offers 2-3 week timeline from DNA arrival to protein delivery using Expi293 and ExpiCHO-S cell lines.
• Functional Analysis Comprehensive functional characterization including SPR-based binding affinity, epitope binning, pH-dependent binding assessment, AlphaScreen/AlphaLISA assays, and cell-based assays (T cell activation, cell killing, proliferation, internalization, degranulation).
• Biophysical Characterization Comprehensive biophysical characterization with GLP-certified labs supporting early-stage developability screening (2-week turnaround) and late-stage lead characterization. Includes melting temperature, aggregation, hydrophobicity, accelerated stability, and forced degradation studies.
• Cell Line Engineering Gene editing and cell line customization using HEK293, Jurkat, CHO-K1 or preferred cell lines. Services include knock-out, over-expressing, and reporter cell lines with functional validation.
• Cell Line Development Stable cell line development using CHO GS-/- platform achieving 4-8 g/L yields and up to 60 generations stability. 16-20 week timeline from gene to Research Cell Bank (RCB). Clinically validated with >100 molecules in clinical stages.
• Biologistics 360-degree lifecycle management of biological samples including cloud-based inventory management, cold storage (-80°C to -196°C), and global shipping with full traceability.
• Cryo-EM Services State-of-the-art cryo-electron microscopy structural biology services utilizing two ThermoFisher Titan Krios 5 systems. Delivers high-resolution maps and atomic models in 2-3 weeks, supporting structure validation, epitope mapping, multiplex mapping, and structure-based design.
• Structure-Based Design Computational protein design service using physics-based and AI-based methods for affinity maturation, antibody humanization, and protein stabilization. Delivers results in 6 weeks including production and screening of designs.
• Mammalian Display Proprietary clinically validated antibody engineering platform that enables selection of antibodies with optimal biophysical properties through FACS screening. Allows assessment of IgG, VHH, bispecifics, CAR-T, and TCR candidates directly in final therapeutic format during discovery. Offered as an out-licensing capability via the Cambridge site.
• Explorer Library Modular flexible antibody platform powered by diverse human-inspired antibody library and Mammalian Display, achieving potency, affinity, and developability in desired therapeutic antibody format. Potential to explore 1.0E+27 modular antibody diversity.
• SuperHuman Libraries Next-generation synthetic fully human antibody library computationally optimized for diversity and developability. SuperHuman 2.0 offers >76 billion clones. Proven clinical success with >4 candidates in clinical phase, and enables identification of thousands of unique high-affinity hits in as little as eight weeks.
• Cosmic Library Newest and largest synthetic antibody library at 100 billion clones, offering high rates of diversity, thermostability, and non-immunogenicity for therapeutic antibody discovery.
• Tungsten Libraries Nanobody (VHH) libraries available in fully camelid or humanized IGVH3-23 framework options, both computationally designed with optimized camelid CDRs for therapeutic development.
• Yeast Display Advanced antibody discovery platform combining phage panning with high-throughput yeast screening for enhanced binder diversity and precision. Includes FACS screening, single-cell sorting, and flow cytometry-based binding validation.
• B-Cell Navigator Dual-engine single B-cell screening platform that screens memory B-cells and plasma cells in parallel, providing access to the complete immune repertoire rather than a fraction. Integrates with developability assessment to design molecules from the first sequence and connects with AbTherx Atlas transgenic mouse technologies.

Quantifiable outcome

• 19+ antibodies advanced to clinical stages (including Phase III) over the past decade
• +6 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature10 records

Partnerships

Five partnerships are on record, tiered core.

• AbTherx, Inc.coreStrategic or Co-development Partner · 23 June 2026FairJourney Bio partnered with AbTherx to bring transgenic mouse-based antibody discovery in-house. The agreement grants access to AbTherx's Atlas Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies. These feed into FairJourney Bio's B-Cell Navigator platform across its global sites in Porto, Cambridge, and San Diego, enabling partner programs to run from immunization to a developability-assessed lead in a single continuous workflow. The Atlas Mice were engineered by the team behind HuMAb Mouse which gave rise to 13 marketed antibody therapeutics. The partnership was announced at BIO International Convention 2026.
• Thermo Fisher ScientificcoreTechnology or IntegrationFairJourney Biologics operates as Europe's leading investor and adopter of highly specialized equipment from leading manufacturers in the global life science market. The company utilizes ThermoFisher Titan Krios 5 systems at its San Diego cryo-EM facility, ensuring scientists are consistently equipped with cutting-edge technology.
• IONTAS LimitedcoreStrategic or Co-development PartnerIONTAS, co-founded in 2012 by John McCafferty (pioneer of antibody phage display technology, 2018 Nobel Prize in Chemistry), was acquired by FairJourney Biologics in 2020. IONTAS operates as FairJourney's Cambridge site, contributing Mammalian Display technology and licensing operations. McCafferty's pioneering work directly underlies FairJourney's phage display capabilities.
• CHOZN Platform (MilliporeSigma)coreTechnology or IntegrationFairJourney Biologics' cell line development service utilizes the licensed CHOZN platform (MilliporeSigma/EMD Millipore), which has generated over 100 molecules in clinical stage and several on market. The CHO GS-/- cells adapted to suspension growth in chemically defined, animal component-free media enable rapid cell line development.
• The Antibody SeriescoreGTM or Marketing PartnerThe Antibody Series is an annual scientific conference organized by FairJourney Biologics that brings together world-renowned experts in antibody discovery and development. After five years of success, the 2025 edition was held in Porto, Portugal (September 9-12), and the 2026 edition is scheduled for Évora, Portugal (September 16-18). The event serves as a key marketing platform for showcasing FairJourney's capabilities and building industry relationships.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• AbCellera Biologics: Public antibody discovery CRO providing technology platforms for therapeutic antibody discovery and development. Comparable as a direct competitor in antibody discovery services using proprietary display and screening technologies, targeting similar pharma and biotech customers.
• Adimab: Private antibody discovery CRO using yeast display and other proprietary platforms. Closely comparable to FairJourney in business model (fee-for-service antibody discovery), customer base (pharma and biotech), and emphasis on developability and lead quality.
• Twist Bioscience: Public synthetic biology company offering antibody discovery services including synthetic antibody libraries. Comparable through competing library offerings and antibody discovery partnerships, though with a broader synthetic biology portfolio.

Broad incumbents

• Distributed Bio (Charles River Laboratories): Charles River's antibody discovery division following its acquisition of Distributed Bio. Directly competes in antibody library and discovery services, now with the scale and capital backing of a major public CRO (Charles River Laboratories).
• GenScript ProBio: Biologics CDMO and discovery services arm of GenScript, offering antibody discovery, engineering, and manufacturing. Comparable as a broader incumbent with overlapping antibody discovery capabilities and significantly greater manufacturing capacity.
• WuXi Biologics: Global leader in biologics contract development and manufacturing with substantial antibody discovery capabilities. Comparable as a much larger incumbent offering end-to-end biologics services from discovery through commercial manufacturing.
• Lonza Biologics: Major public CDMO with biologics services spanning cell line development, process development, and manufacturing. Overlaps with FairJourney's cell line development and CHO GS-/- platform capabilities, though Lonza operates at significantly larger scale.
• Bio-Techne: Public life sciences tools and services company with antibody-related reagents and services. Comparable through its GMP-grade cytokines and reagents supporting antibody discovery workflows, plus protein production services that overlap with FairJourney's offerings.

Emerging players

• Yumab: Private antibody discovery CRO specializing in phage display and single B-cell screening. Comparable as a smaller-scale specialist with overlapping technology platforms and similar target customers in mid-cap biotech and academic centers.
• Sino Biological: China-based reagent and CRO provider with growing antibody discovery and production services. Comparable as an emerging competitor in recombinant antibody production and custom antibody services, particularly relevant for Asia-Pacific customer acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@fjbio_
• LinkedInlinkedin.com/company/fairjourney-biologics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fairjourney Biologics